Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: quavonlimab, zalifrelimab, cadonilimab +3 | 0.90 |
| trials ClinicalTrials.gov | 21 Parkinson's trials, 1 stopped | 0.96 |
| literature PubMed | 8 Parkinson's papers of 15,271 | 0.71 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6835
Sealed predictions
- CTLA4 in dopamine neurons, braak-0.58 (p 0.104) → +0.34 (p 0.373)receipt 6844
Swarm cases
receipt 6844: CTLA4 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.949, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.658, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.820, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 5; without severely affected donors -0.02 (p 0.949, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CTLA4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts